Key facts
- This page summarizes Jakob Dupont's Form 4 filing for Bolt Biotherapeutics, Inc. (BOLT).
- 8 reported transactions and 8 derivative rows are listed below.
- Accepted by SEC: 16 Dec 2025, 17:15.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Disposed to Issuer
Award
Disposed to Issuer
Award
Disposed to Issuer
Award
Disposed to Issuer
Additional SEC filing notes
Footnote F1
For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control.
Footnote F2
The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price.
Footnote F3
The option is fully vested and exercisable.
Footnote F4
The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price.
Footnote F5
The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.
Footnote F6
The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Footnote F7
The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.